Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lieven Annemans

Showing results (61-70 of 261) with videos related to

Pageof 27
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2010
Economic impact of enoxaparin after acute ischemic stroke based on PREVAILGraham Pineo, Jay Lin, Lee Stern, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 30, 2007
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in BelgiumLieven Annemans, Daniëlle Strens, Erica Lox, et al.
Acta Clinica Belgica|December 27, 2021
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in BelgiumWinde Jorissen, Lieven Annemans, Nicolas Louis, et al.
Journal of Telemedicine and Telecare|October 29, 2013
Cost-effectiveness of a helpline for suicide preventionLore Pil, Kirsten Pauwels, Ekke Muijzers, et al.
Pharmacoeconomics|December 21, 2004
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseasesJasper M Bos, Philippe Beutels, Lieven Annemans, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|November 29, 2007
Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseasesLieven Annemans, Mark Lamotte, Peter Clarys, et al.
Diabetes Care|January 30, 2002
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patientsMark Lamotte, Lieven Annemans, Aurelia Lefever, et al.
Journal of Evaluation in Clinical Practice|December 4, 2014
Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groupsBarbara O M Claus, Hugo Robays, Johan Decruyenaere, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 21, 2014
EQ-5D versus SF-12 in coronary patients: are they interchangeable?Delphine De Smedt, Els Clays, Lieven Annemans, et al.
European Journal of Public Health|March 27, 2023
Cost of illness in patients with post-treatment Lyme disease syndrome in BelgiumRuben Willems, Nick Verhaeghe, Christian Perronne, et al.
Pageof 27

Showing results (61-70 of 261) with videos related to

Sort By:
Pageof 27
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2010
Economic impact of enoxaparin after acute ischemic stroke based on PREVAILGraham Pineo, Jay Lin, Lee Stern, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 30, 2007
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in BelgiumLieven Annemans, Daniëlle Strens, Erica Lox, et al.
Acta Clinica Belgica|December 27, 2021
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in BelgiumWinde Jorissen, Lieven Annemans, Nicolas Louis, et al.
Journal of Telemedicine and Telecare|October 29, 2013
Cost-effectiveness of a helpline for suicide preventionLore Pil, Kirsten Pauwels, Ekke Muijzers, et al.
Pharmacoeconomics|December 21, 2004
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseasesJasper M Bos, Philippe Beutels, Lieven Annemans, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|November 29, 2007
Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseasesLieven Annemans, Mark Lamotte, Peter Clarys, et al.
Diabetes Care|January 30, 2002
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patientsMark Lamotte, Lieven Annemans, Aurelia Lefever, et al.
Journal of Evaluation in Clinical Practice|December 4, 2014
Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groupsBarbara O M Claus, Hugo Robays, Johan Decruyenaere, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 21, 2014
EQ-5D versus SF-12 in coronary patients: are they interchangeable?Delphine De Smedt, Els Clays, Lieven Annemans, et al.
European Journal of Public Health|March 27, 2023
Cost of illness in patients with post-treatment Lyme disease syndrome in BelgiumRuben Willems, Nick Verhaeghe, Christian Perronne, et al.
Pageof 27